NCT01567059: Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
|
|
| Completed | 2 | 34 | US | tosedostat, aminopeptidase inhibitor CHR-2797, CHR-2797, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, decitabine, 5-aza-dCyd, 5AZA, DAC | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Acute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia | 06/13 | 06/13 | | |
